<?xml version="1.0" encoding="UTF-8"?>
<p id="Par13">In a study by Finiuk et al., new N-acylated-2-amino-5-benzyl-1,3-thiazoles were prepared and assessed for their in vitro anticancer activity. The selectivity of tested compounds against glioblastoma and melanoma were proved in MTT assay and among these compounds, compound 
 <bold>11</bold> demonstrating a selective action towards the human glioblastoma U251 cells and human melanoma WM793 cells, comparing to the leukemia cells. Meantime, these compounds created low toxicity to pseudo-normal cells (Fig. 
 <xref rid="Fig4" ref-type="fig">4</xref>) [
 <xref ref-type="bibr" rid="CR39">39</xref>].
</p>
